ASCO: Studies pave the way on immunotherapy clinical trials for rare, aggressive cancers
Several MD Anderson-led studies at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting focus on using immunotherapy to provide new treatment options for rare, aggressive cancers, including anaplastic thyroid cancer (ATC), glioblastoma, leptomeningeal disease (LMD) and soft-tissue sarcomas. For most of these rare diseases, survival is poor and few – if any – effective treatment options are currently available.
As...
Study shows naproxen promotes immune activation in Lynch syndrome patients
A Phase I chemoprevention clinical trial led by MD Anderson researchers found that naproxen, an over-the-counter anti-inflammatory drug, is...
Scientific communication predicts research career intention
“Trainees at the Ph.D. and postdoctoral level are leaving the academic research track at alarming rates, and disproportionately if they’re...
Extending cervical cancer prevention around the world
While U.S. cervical cancer rates have fallen by 70% since the 1950s thanks to the Pap test and national screening programs, the disease remains a leading killer of women in low- and middle-income countries for lack of access to screening and trained providers.
Kathleen Schmeler, M.D., professor of Gynecologic Oncology and Reproductive Medicine, is working change this. Her work to prevent and treat cervical cancer has taken...
E-cigarettes: Unstandardized, under-regulated, under-studied – safety unknown
The recent outbreak of lung injury and death associated with e-cigarettes and vaping has led to a renewed scrutiny of electronic nicotine...
Multiple studies show major lack of public knowledge about HPV vaccine and cancer prevention
Despite the fact that the human papillomavirus (HPV) vaccine has been available in the U.S. for over 10 years and remains the only vaccine...
Studies show early success for pre-surgical immunotherapy in liver cancer, cutaneous head and neck cancer
Early results from two MD Anderson studies show promising responses to neoadjuvant (pre-surgical) checkpoint inhibitors in patients with advanced...
Predicting head and neck cancer treatment toxicities with machine learning
MD Anderson researchers have developed the first machine learning algorithm to predict acute toxicities in patients receiving radiation therapy...
Research finds evidence HPV vaccine is improving herd immunity
A study from researchers at The University of Texas MD Anderson Cancer Center found that the prevalence of the types of oral human papillomavirus...